Aspire Biopharma Holdings (ASBP) Cash from Operations (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Cash from Operations came in at 3038522.0 in Q1 2026, down 73.48% year-on-year from 11456763.9 in Q1 2025, and down 227.48% on a QoQ basis from 927841.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Cash from Operations (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 6 years of Cash from Operations data on file, last reported at 3038522.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 73.48% year-over-year to 3038522.0 in Q1 2026; TTM through Mar 2026 was 6210482.0, a 240.53% decrease from a year earlier, with the FY2025 full-year figure at 4923488.0, down 1756.62% from the prior year.
- Cash from Operations for Q1 2026 stood at 3038522.0, down from 927841.0 in the prior quarter.
- Over the last five years, Cash from Operations for ASBP reached as high as 479569.0 in Q4 2024 and fell as low as 3038522.0 in Q1 2026.
- Historically, Cash from Operations has averaged 605240.53 across 5 years, with a median of 189951.0 in 2023.
- Across the five-year window, Cash from Operations surged 407.16% in 2024 and sank 1927.43% in 2025, its largest moves.
- Year by year, Cash from Operations stood at 35870.0 in 2022, then plunged by 335.26% to 156128.0 in 2023, then jumped by 407.16% to 479569.0 in 2024, then tumbled by 293.47% to 927841.0 in 2025, then plunged by 227.48% to 3038522.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 3038522.0 in Q1 2026, 927841.0 in Q4 2025, and 1103809.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Aspire Biopharma Holdings | 1.09 Mn | -733,865.14 | 5,750.00 | -3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.04 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Dec 31, 2025 | -927,841.00 |
| Dec 31, 2025 | -927,841.00 |
| Sep 30, 2025 | -1.10 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | 479,569.00 |
| Dec 31, 2024 | 479,569.00 |
| Sep 30, 2024 | -495,540.00 |
| Sep 30, 2024 | -495,540.00 |
| Jun 30, 2024 | -56,244.00 |
| Jun 30, 2024 | -56,244.00 |
| Mar 31, 2024 | -192,971.00 |
| Mar 31, 2024 | -192,971.00 |
| Dec 31, 2023 | -156,128.00 |
| Dec 31, 2023 | -156,128.00 |